Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and etest for Candida species isolates

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1347-1350

  Espinel Ingroff, Ana ^a   Canton, E ^b   Peman, J ^b   Martin Mazuelo E ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN;

ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; EPSILOMETER TEST; FUNGAL STRAIN; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; SPECIES;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; REFERENCE STANDARDS;

EID: 77149132110     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01324-09     Document Type: Article

References (31)

1. Alexander, B. D., T. C. Byrne, K. L. Smith, K. E. Hanson, K. J. Anstrom, J. R. Perfect, and L. B. Reller. 2007. Comparative evaluation of Etest and Sensititre YeastOne panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J. Clin. Microbiol. 45:698-706.
2. Arendrup, M. C., G. Garcia-Effron, W. Buzina, K. L. Mortensen, N. Reiter, C. Lundin, H. E. Jen̈sen, C. Lass-Flörl, D. S. Perlin, and B. Bruun. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193.
3. Arendrup, M. C., S. Perkhofer, S. J. Howard, G. Garcia-Effron, A. Vishukumar, D. Perlin, and C. Lass-Flörl. 2008. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob. Agents Chemother. 52:3504-3511.
4. Baixench, M.-T., N. Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, S. Ramires, C. Piketty, and E. Dannaoui. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
5. Barchiesi, F., E. Spreghini, S. Tomassetti, A. Della Vittoria, D. Arzeni, E. Manso, and G. Scalise. 2006. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob. Agents Chemother. 50:2719-2727.
6. Cantón, E., J. Pemán, M. Sastre, M. Romero, and A. Espinel-Ingroff. 2006. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob. Agents Chemother. 50:2829-2832.
7. Cantón, E., J. Pemán, A. Valentín, M. Bosch, and A. Espinel-Ingroff. 2007. Pharmacodynamics of anidulafungin against six Candida species. J. Chemother. 19(Suppl. 3):42.
8. Cantón, E., J. Pemán, A. Valentín, A. Espinel-Ingroff, and M. Gobernado. 2009. In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. Antimicrob. Agents Chemother. 53:3108-3111.
9. Chryssanthou, E., and M. Cuenca-Estrella. 2002. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40:3841-3844.
10. Clinical and Laboratory Standards Institute. 2007. Development of in vitro susceptibility testing criteria and quality control parameters; approved standard, 3rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; informational supplement, 3rd ed. CLSI document M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Desnos-Ollivier, M., S. Bretagne, D. Raoux, D. Hoinard, F. Dromer, and E. Dannaoui. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52:3092-3098.
14. Desnos-Ollivier, M., F. Dromer, and E. Dannaoui. 2008. Detection of caspofungin resistance in Candida spp. by Etest. J. Clin. Microbiol. 46:2389-2392.
15. Douglas, C. M., J. A. D'Ippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz. 1997. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.
16. Espinel-Ingroff, A. 2003. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 41:403-409.
17. Espinel-Ingroff, A., E. Canton, E. Martin-Mazuelos, and J. Pemán. 2009. Pharmacotherapy of Candida infections with echinocandins. Clin. Med. Ther. 1:889-897.
18. Food and Drug Administration. 2003. Class II special controls guidance document: antimicrobial susceptibility test systems; guidance for industry. Food and Drug Administration, Washington, DC.
19. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
20. Garcia-Effron, G., D. P. Kontoyiannis, R. E. Lewis, and D. S. Perlin. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183.
21. Garcia-Effron, G., S. Park, and D. S. Perlin. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
22. Ghannoum, M. A., C. A. Chen, M. Buhari, J. Chandra, P. K. Mukherjee, D. Baxa, A. Golembieski, and J. A. Vazquez. 2009. Differential in vitro activity of andulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin. Microbiol. Infect. 15:274-279.
23. Jacobsen, M. D., J. A. Whyte, and F. C. Odds. 2007. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob. Agents Chemother. 51:1882-1884.
24. Krause, D. S., J. Reinhardt, J. A. Vazquez, A. Reboli, B. P. Goldstein, M. Wible, and T. Henkel. 2004. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48:2021-2024.
25. Krogh-Madsen, M., M. Arendrupp, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
26. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44:529-535.
27. Pappas, P. G., C. A. Kauffman, D. Andes, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
28. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
29. Pfaller, M. A., V. Chaturvedi, D. J. Diekema, M. A. Ghannoum, N. M. Holliday, S. B. Killian, C. C. Knapp, S. A. Messer, A. Miskov, and R. Ramani. 2008. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J. Clin. Microbiol. 46:2155-2159.
30. Pfaller, M. A., S. A. Messer, K. Mills, A. Bolmstrom, and R. N. Jones. 2001. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J. Clin. Microbiol. 39: 4387-4389.
31. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.